According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
He will continue to lead business in LATAM and Asia regions in this new role
The companies plan to use the proceeds to retire debt and expand operations
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Subscribe To Our Newsletter & Stay Updated
